<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 372 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page371.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=372">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 372 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 372</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=372"><img src="../thumb/372.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Biologicals - 26                                                               2020-04 / 335
       Squam.cell head & neck Ca: Start Erbitux treatm.1 wk. bef. radiat.  Contraindications: Chron.myelodysplast.syndr., chron.myeloid   intravasc./SC/ intraderm. use, have appropr.medic.treatm.avail.in
       ther.& contin.unt.end of radiat. ther. per.  leukaem., sev.congenit.neutropen. with abnorm.cytogen., to incr.  event of rare anaphylact. reacts., protect.of all vacc. recipients may
       Recurr.&/metast.squam. cell head/neck Ca: Use in combin.  cytotox.chemother. dos. beyond est.regimens, imp.ren./hepat.  not result., not intend.for treatm. of act.genit.les./cervic./vulv.or vag.
       with up to 6 cycl.of platin.based chemother.foll.by maint ther.unt.  funct., pregn.& lactat.  Ca/ CIN/ VIN or VaIN, no protect.against dis.not caus. by HPV, monit.
       dis.progress. Chemother.not to be admin.earlier than 1 hr aft. end   Side effects: Musculoskelet.pain, urin. abnormalit. predom.mild   pts.for approx.15 min.aft.admin.in case of syncope/fall., low.grade
       of Erbitux infus.             to mod.dysur., splenomegaly, spleen.rupt., sickle cell crisis, hyper-  fev./mild resp. infect. not gen.C/I to vaccinat., reduc.antibody respons.
       Refer to respect.prod.inform.when used with concom. other agents.  sens., Graft vs.Host dis., pseudogout, headache, hypotens., veno-  to act.immunisat.in imp.immune responsiven.
       Contraindications: Known hypersens.reacts.to cetuximab., effic.  occlus.dis.& fluid vol.disturbs., capillary leak syndr., oropharyngeal
       in paed.pts.below 18 yrs not est., safety in pregn.& lactat.not est.,   pain, cough, dyspn., haemoptys., ac.resp.distress syndr., reasp.fail.,   HAVRIX, GSK [P/S]
       determin.mutat. status by accredit.lab.using validat.test methods for   pulm.oed.., interstit lung dis., lun infiltrt., pulmon.haemorrh., GIdis-  Formaldehyde-inactivat.hepatit.A virus vaccine (HM175 hepatitis A
       KRAS & NRAS (exons 2,3 & 4) mutat, combin. with oxaliplatin-cont.  turbs., alopec., skin rash, Sweet’s syndr., cutan.vasculit., chest &   virus strain) adsorbed onto Al hydrox.
       chemother.in mutant RAS metastat. colorect.Ca or for whom RAS   unspec.pain, exacerbat.of rheumatoid.arthrit., asthen., fatig., mu-  Indications: Act.immunisat.against HAV infects.in subj.at risk
       mCRC status is unknown, negat.benef:risk bal.with tumours bear.  cos.inflammat., pain.  (S4) 1440 INJ, [P/S] 29/30.1/0310
       RAS mutat.with negat.effs.on progress. free surviv.& overall surviv.,   Warnings and special precautions: Risk vs. benef.in sickle cell   Not&lt;1440 ELISA units of viral antig./1 ml dos.
       consid.C/I for concom.chermother.agents/radiother., irinotecan/ ra-  dis., spec.care to distinguish diagnos. of blast transformat.of chron.  822361-019: 1x monodos.vial. R309.90
       diother.contraindicat.        myeloid leukaem.from ac.myeloid leukaem., monit.of bone density in   Dosage: IM admin. into deltoid reg. Can be given to HIV infect.per-
       Side effects: Poss.sev.hypomagnesaem., hypokalaem., hypocal-  underly. osteoporot.bone dis.where ther. exceeds 6 mnths., discont.  sons. Each dos.consists of 1 ml sterile susp. HAVRIX 1440: Adults &
       caem./incr.sev.leucopen.& neutropen.esp.with platinum-bas.chem-  ther.at onset of pulm. signs in assoc.with radiolog.signs of pulm.in-  childr.over 16 yrs: Prim.immunisat: One sngl.dos. Booster recomm.
       other., necrotis.fascilit., skin reacts., acne-like rash/ prurit./ dry skin   filtrat & deterior.pulm.funct.poss.prelim.signs of adult resp.distress   betw.6-12 mnths.aft.prim.dos.
       desquamat., hypertrichos.& nail disords., skin necros., alopec., card.  syndr., reg.WBC, neutrophil respons. poss. dimin. in pts.with reduc.  (S4) JUNIOR INJ, [P/S] 31/30.1/0294
       disords., hand-foot syndr., radiat.effs.incl.dermatit./mucosit., dehy-  precursors, Graft vs Host dis.& fatalit.in pts.receiv.G-CSF aft.alloge-  Not&lt;720 ELISA units of viral antig./0,5 ml dos.
       drat., headache, anorex., asept.meningit., conjunctivit., blepharit,   neic bone marr.transplantat., heredit.fruct.intol., elderly.  703448-001: 1x monodos.vial. R196,98
       ulc./keratit., DVT, pulm. embol., interstit.lung dis.with poss.fatalit.,   Interactions: Safety & effic.of Filgrastim Teva given on same day as   Dosage: IM admin. into deltoid reg.or antero-lateral thigh in young
       N&V, incr.in liv.enzym. lev., erysipelas or staphyllococ. scald.skin   myelosuppress.cytotox. chemother. not est., not recomm.24 hrs.bef.to   childr. Can be given to HIV infect. persons. Each dos.consists of
       syndr./sepsis, Stev.John.syndr/tox. epiderm.necrolys., mild to mod.  24 hrs.aft.chemother.in view of sensitiv.of rapid. divid. myeloid.cells   0,5 ml sterile susp.HAVRIX 720. Childr.& adolesc.from 1-16
       infus.relat. reacts.,fatig., fev., chills, dizzin., dyspn., epistax., sev.infus.-  to myelosuppress.cytotox. chemother., interacts.with other haema-  yrs: Prim.immunisat: One sngl.dos. Booster recomm. betw. 6-12
       relat.reacts.somet.fatal develop.dur.1 hr within infus.but may occur   topoiet. growth fact.& cytokines not investigat., Li poss. potent. eff.  mnths.aft.prim.dos.
       sev.hrs.aft./subseq. infus., sev.somet.fatal CV events.    Contraindications: Hypersens.aft.prev.HAVRIX admin., IV admin.
       Warnings and special precautions: Limit. exper. with concom.ra-  GARDASIL, MSD [P/S]  Side effects: Loc.reacts., headache, drowsing., dizzin., hypoaesthes.,
       diother.in colorect.Ca, do not use in colorect.Ca where tumours have   Human Papillomavirus (HPV) 6 L1 prot.20 µg, HPV 11 L1 prot.40 µg,   paraesthes., malaise, fatig., fev., N&V, loss of appet., diarrh., myalg.,
       RAS mutat./ where RAS tumour status unknown, cross. placenta,   HPV 16 L1 prot.40 µg, HPV 18 L1 prot.20 µg/0,5 ml dos.  arthralg., allerg.reacts incl.anaphylax.& convuls., syncope, irritabil.,
       decr.infus.rate in event of mild-mod. infus.-relat.reacts.which are to be   Indications: Prev.in girls & women 9-45 yrs:of cervic./vulv./ vag.   URTI, flu-like illn., chills.
       maint in subseq. infus., immed.discont.ther.dur.sev.infus.-relat. reacts.   & anal Ca caus.by HPV 16 & 18, genit.warts (condylomata acumi-  Special precautions: Do not freeze if frozen discard , postpone in
       (anaphylact.or repres.cytokine release syndr) & instit.emerg.treatm.,   nata) caus.by HPV 6 & 11.  cas.of ac.sev.febr.illn., if subj. in incubat.period at time of immunisat.
       warn.pts.of poss. late hypersens.reacts.& to contact med.prof., incr.   Prev.of follow.infects.& precancer./dysplast. les. caus.by HPV   eff.is not known, in haemodial.pts.& pts.with imp.immune syst.adeq.
       anaphylact.react.risk in hist.of red meat/tick bite allergy/posit.cetuxi-  6, 11, 16 & 18: Cervic. intraepithel. neoplas.grade 2 & 3, cervic. ande-  antibod.titres may not be obt.aft.prim. immunisat.course and addit.
       mab IgE antibod.results, reduc. perform.status/pre-exist.card.-pulm.  nocarcin. in situ, cervic.intraepithel. neoplas. grade 1, vulv. intraepi-  dos.may be necess.& antibody titres recomm., gluteal reg./SC/ intra-
       dis., discont.& treat. if interstit. lung dis.(ILD) diagn., chemother. assoc.  thel.neoplas.grade 2& 3, vag. intraepithel. neoplas.grade 2 & 3, vulv.   derm. admin.may result in less than optim. antibody respon., medic.
       with ILD & pre-exist.pulm.dis.report.in fatal ILD cases, interupt.ther.  intraepithel. neoplas.grade 1, vag.intraepithel. neoplas. grade 1, anal   supervis.30 mins.aft. admin recomm., thrombocytopen., bleed.disor-
       if sev. skin reacts.&gt; grade 3 develop & only resume if react. resolv.to   intraepithel. neoplas.grades 1,2 & 3.  ds., in pregn.& lactat.only when clearly need.since eff. not assess.,
       grade 2, treatm.to be resum.at low. dos. lev.with 2nd & 3 occur.of sev.  Protect.in girls & women 9-26 yrs against HPV 31, 33, 52, 58-relat.  admin.other vaccines/ immunoglobulins at diff.inj.sites, do not mix
                              rd
                           th
       skin reacts., discont.ther.if sev.skin reacts. occur 4  time which do not   cerv.intraepithel.neoplas. grades.  with other vaccines/immunoglobulins in same syringe.
       resolv.to grade 2, consid.prophylact.oral tetracycl.& topic. hydrocortis.   Prev.in boys & men 9-26 yrs. Extern.genit.les. /infect. & follow.dis.  HEBAGAM IM, NBI [P/S]
       & moistur.applic.for skin reacts., ser. electrol.lev.prior to & dur.ther.,   caus. by HPV types incl.in vacc: Anal Ca caus.by HPV 16 & 18, genit.  Human hepatit.B immunoglob.deriv.from pooled human plasma with
       electrol.replet.as appropr., incr.risk of sev.neutropen.with platin.-based   warts (condyloma acuminata) caus.by HPV types 6 and 11, prev. of   high titre of antibodies to HBsAg, test.& found non-react.to HBsAg &
       ther.which poss.lead to febr.neutropen./ pneumon./sepsis, caref.monit.  anal intraepithel. neoplas.grades 1,2 & 3 pre-cancer.or dysplast.les.  antibodies to HCV, HIV-1 & HIV-2 viruses.
       esp.with skin les./ mucosit./diarrh.that poss.facilit.infect.occur., breast   caus.by HPV 6, 11, 16 & 18.  Indications: Hepatit.B post-expos.prophylax., temp. protect.of infts.
       feed. not recomm.until 2 mnths.aft.last dos., limit.exper.in pts.75 yrs &   (S2) INJ, 41/30.1/0145  born to HBsAg+.mothers., haemodial.pts.until vaccin.effect., subj.not
       over, incr.CV effs. in combinat.with fluoropyrimidines compar.to that   710249-001: 1x sngl.dos syr., R853,23  show. immun.respon.aft.vacc.for whom contin.prevent. necess.due
       with fluoropyrimidines, CV status & concom. cardiotox. cmpds.t o be   Dosage: Admin. ASAP aft.remov.from refrigerat. Complete vacci-  to contin.hepatit.B infect.risk
       taken into account, ophthalm. consult. if S&S of keratit., discont./ interr.  nat.course with Gardasil.  (S4) IM INJ. T/30.2/746. 100 IU/ml.
       ther.& cons.benef./risk of cont.ther.if keratit. diagn., keratit.hist./sev.dry   Childr.& adolesc: 9-17 yrs., women 18-45 yrs, men 18-26 yrs:   731501-004: 1x2 ml amp, R841,22
       eyes/cont.lens., not stud.in pre-exist.haematolog.disords., induc.skin   IM admin.as 3 separat.0,5 ml dos. 1  dos: Elected date. 2  dos: 2   Dosage: Warm amp.to body temp.bef.use. Admin. as sngl.dos.,
                                                             nd
                                                    st
       les. predispos. pts.to superinfects.& subseq. complicat.  mnths aft.1  dos. 3  dos: 6 mnths aft. 1  dos.  first dos.of vaccine can be inject.on same day as human hepatit.B
                                          st
                                                     st
                                             rd
       Drug interactions: No formal stud.perform.in human. other than   Encourage adher.to above sched.however effic. demonstrat.where   immunoglob.but at diff.site.
       with irinotecan.              all 3 dos.receiv.within a 1 yr. period. If altern.sched.necess.admin.2   nd  Needle-stick injury, mucosal/sex. expos: &lt;5 yrs: 200 IU. 5-9 yrs:
       See also MDR page 492.        dos.at least 1 mnth.aft.1  dos.& 3  dos.at least 3 mnths. aft.2  dos.  300 IU. &gt;10 yrs: 500 IU. Treat within 48 hrs.& not more than 7 days aft.ex-
                                                              nd
                                                   rd
                                               st
       EUVAX B INJ, Specpharm [P/S]  Alternat.sched. 9-13 yrs: Admin.accord.to a 2-dose (0, 6 mnths./0,   pos. Rep. aft.28 days unless immunity is shown/ hepatit. B vaccine admin.
       Hepatit.B virus recomb.-DNA surf.antig.  12 mnths.) sched.  Newborn inft.born to HBsAg posit.mothers protect: 200 IU
                                     Contraindications: Re-admin.to indiv.develop. sympts.indicat.
       Indications: Act.hepatit.B virus immunizat.                immed./within 48 hrs.of birth combin. with act.immunizat.(at diff.
       (S2) INJ. 35/30.1/0024        of hypersens., safety in pregn.& lactat.not est. no adeq./well-  sites). Admin. may need to be repeat.until seroconvers. follow. vacc.
                                     control.stud.in pregn. women, safety & effic.not eval.in childr.
       713048-002: 20 µg/1 ml sngl. dos., R110,02                 Haemodialysis: 8-12 IU/kg (max 500 IU). Admin. may need to be
       Dosage: Admin.IM. Neonates & childr.10 yrs. & young: 0,5 ml   und.9 yrs./ adults above 45 yrs., safety/immunogenic.& effic. not   repeat.every 2 mnths. Until seroconvers. follow.vacc.
       (10 µg) First dos.at elect.date (6 wks.of age for neonates) 2  dos:   full eval.in HIV infect.  Subj.not show.immun.resp.aft.vacc.for whom contin.prevent.
                                nd
                      st
       1 mnth later. 3  dos: 6 mnths aft. 1  dos.  Side effects: Loc.reacts.incl.pain/cellulit./ swell./erythem./hae-  necess: Adults: 500 IU. Childr: 8 IU/kg. Admin.every 2 mnths. Min.
             rd
       Adults & childr.over 10 yrs: 1 ml (20 µg) Same sched. as above.  matom., pyrex., bronchosp., idiopath. thrombocytopen.purp., lym-  protectiv. antibod. titre is consid.to be 10 IU/L.
                        st
       Altern. sched. for high-risk groups: 1  dos.at elect. date (6 wks   phadenopath., ac. dissem.encephalomyelit., dizzin., Guillain-Barre   Contraindications: Bleed.disords., IV admin., weigh risk-benef.
       of age for neonates); second dos. 1 mnth later; 3  dos. 2 mnths.  syndr., headache, dizzin., syncope somet.with clon.-tonic movem.,   ratio in pts.with IgA defic.hist.or sev. anaphylact.reacts.to plasma
                            rd
       aft.1  dos.                   N&V, arthralg., myalg., asthen., chills, fatig., malaise, hypersens./   products, safety in pregn. & lactat.not est., treatm.of any type of
         st
       Contraindications: Safety in pregn.not est., effic. in immunocom-  anaphylact. reacts., urticar.  hepatit. B infect.
       prom./immunosuppress.pts.not est., IV/ intraderm.admin.  Special precautions: Do not use interchang.with other HPV vacc.,   Side effects: Loc.reacts., headache, fev., chills, flush, lightheadedn.,
       Side effects: Loc.reacts., system.reacts.incl.fev., dizzin., headache,   thrombocytopen./any coagulat. disords. as bleed.poss., women.found   backache, naus., skin/ anaphylact.reacts., IgA sensitisat., impair.ef-
       Guillain-Barre syndr., neuropathy incl.hypoesthes./sev.CNS disord.  to be pregn. bef. complet.of dos.regim.instruct.to defer complet. of   ficacy live attenuat.virus vaccines.
       Special precautions: Lactat., sev.comprom. cardiopulmon. sta-  vaccinat.regim.until pregn.resolut., nurs. women, not recomm.for   Special precautions: Act.hepatit.B immunisat. pref. for persons
       tus., febr./system.reacts.poss. risk, epinephrine to be avail.in case   at contin.risk, delay live virus vaccinat. for 3 mnths.aft.treatm., in-
       of anaphylax., due to long incubat.period an undiagn.infect.may be   fect.dis. transmiss. cannot be tot.exclud., admin.in. div.dos. at diff.
       pres.& hepatit.B will not be prevent., cons. benef.-risk ratio in delay.  sites if large vol.(&gt;2 ml for childr./&gt;5 ml for adults) reqd., do not mix
       vaccinat.in cases of sev. act. infect.  Mono amine oxidase   with other prods.
       FILGRASTIM TEVA, Teva [P/S]        inhibitors (MAOI) have   HEBERBIO HBV, Biovac Instit. [P/S]
       Filgrastim.                                                Hepatit.B virus recomb.-DNA surf.antig.
       Indications: Reduct.in neutropen.durat.in pts. receiv.cytotox.  a prolonged action,   Indications: Act.hepatit.B virus immunizat.
       chemother.except.in pts.with chron. myeloid leukaem.& myelod-  (S2) INJ. 36/30.1/0358, 0359
       ysplast.syndr.                     so patients should not   701658-001: 10 µg/0,5 ml sngl.paed.dos., R73,95
       (S4) SOL.FOR INJ/INFUS, 46/32.16/0317, 0318. 60 MIU(600 µg)/ml  701659-001: 20 µg/1 ml sngl.adult dos., R101,94
       3000141-001: 30 MIU/0,5 ml, 5x pre-filled syr, R3 794,76  take any of the foods   Dosage: Admin.deep IMI. Neonates & childr. 10 yrs. & young:
                                                                                  nd
                                                                                         rd
       3000142-001: 48 MIU/0,8 ml, 5x pre-filled syr, R6 071,60  or medicines known   0,5 ml. Neonates: First dos.at 6 wks. 2 dos: 10 wks. 3 dos: 14 wks.
       Dosage: Admin.only in collaborat.with G-CSF treatm.exper.oncology   Adults & childr.over 10 yrs: 1 ml. First dos.at elect.date; second
       centre with the necess. diagnost.facilit.  to cause reactions for   dos.1 mnth later; 3 dos. 2 mnths.aft.1  dos.
                                                                          rd
                                                                                  st
       Est.cytotox.chemother: Recomm.dos: 0,5 MIU (5 µg)/kg/day.   Contraindications: Fev.due to sev.infects., IV admin., safety in
       Do not admin.within 24 hrs.of cytotox. chemother. Admin.as dly SC   at least 14 days after   pregn.& lactat.not est., effic.in immunocomprom./immunosup-
       inj/IV infus. dil. in 5% gluc.sol.over 30 mins. Cont.till expect. nadir is   press.pts.not est.
       passed & neutrophil count recover.to norm. range (±14 days). Premat.  stopping treatment.  Side effects: Loc.reacts., system.reacts.incl.fev., headache, naus.,
       discont.not recomm. Treatm.durat.may be up to 38 days in ac. my-  weakn., poss.sudd.& life-threat. react.
       eloid leukaem treatm. Do not mix.with NaCl sols. Paed.dos.recomm.  Special precautions: Sev.comprom.cardiopulm. status., febr./sys-
       same as for those in adults receiv.myelosuppress.cytotox.chemother.  tem.reacts.poss. risk, due to long incubat.period an undiagn.infect.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page371.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page367.html">367</a>&nbsp;&nbsp;&nbsp;<a href="page368.html">368</a>&nbsp;&nbsp;&nbsp;<a href="page369.html">369</a>&nbsp;&nbsp;&nbsp;<a href="page370.html">370</a>&nbsp;&nbsp;&nbsp;<a href="page371.html">371</a>&nbsp;&nbsp;&nbsp;<a href="page372.html">372</a>&nbsp;&nbsp;&nbsp;<a href="page373.html">373</a>&nbsp;&nbsp;&nbsp;<a href="page374.html">374</a>&nbsp;&nbsp;&nbsp;<a href="page375.html">375</a>&nbsp;&nbsp;&nbsp;<a href="page376.html">376</a>&nbsp;&nbsp;&nbsp;<a href="page377.html">377</a>
             </td>
             <td width="35%"><a href="page373.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page373.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
